Table 1.
Study populations
| N | 9152 |
| Age (years) | |
| Mean (SD) | 44.4 (21.0) |
| Not reported/unknown | 281 |
| Sex | |
| Female | 4155 (45.4) |
| Male | 4993 (54.6) |
| Not reported/unknown | 4 |
| Country of publication | |
| China | 9002 (98.4) |
| France | 101 (1.1) |
| Singapore | 19 (0.2) |
| USA | 9 (0.1) |
| Taiwan | 6 (0.1) |
| Korea | 3 (0.03) |
| Germany | 2 (0.02) |
| Italy | 2 (0.02) |
| UK | 2 (0.02) |
| Vietnam | 2 (0.02) |
| Afghanistan | 1 (0.02) |
| Japan | 1 (0.01) |
| Scotland | 1 (0.01) |
| Spain | 1 (0.01) |
| COVID-19 testing | |
| Testing method reported | 8357 (91.3) |
| Testing method not reported | 795 (8.6) |
| Hospitalized | |
| Yes | 8997 (98.3) |
| No | 143 (1.6) |
| Not reported | 12 (.1) |
| ICU stay required | |
| Yes | 1017 (11.1) |
| No | 4112 (44.9) |
| Not reported | 4023 (44.0.) |
| Ventilator required | |
| Yes | 1672 (18.3) |
| No | 5564 (60.8) |
| Not reported | 1916 (20.9) |
| Author-defined severity | |
| Severe | 2470 (27.0) |
| Not severe | 5031 (55.0) |
| Not reported | 1651 (18.0) |
Data are mean (SD) or n/N (%), unless otherwise specified